Libra Infusions' losses widened 23 per cent year-on-year in the nine months through March 2021 as the company published pending quarterly results on Monday.
It has reported a loss of Tk 6.44 per share in the nine months through March 2021, increased from Tk 5.24 per share a year ago.
Even after the disclosure of the quarterly financial statements, investors are in the dark about the company's performance in the FY21 and the FY22.
Despite the Libra Infusions' failure to provide the recent data, its stock went higher crossing Tk 1,000 in July this year before it came down to the floor at Tk 883.60 on September 20.
The company incurred loss for the first time in the FY20, leading to the EPS of Tk 7.88 in the negative. But it disbursed 5 per cent cash dividend for the year.
The loss was due to an acute shortage of working capital, said company Secretary Md Shafiqul Islam Bhuyan.
Libra Infusions' business started to decline in the FY19 owing to disputes with its financier Al-Arafah Islami Bank.
The company built a second unit at its factory complex in Mirpur, Dhaka, but the bank's non-cooperation hampered business.
The Bangladesh Securities and Exchange Commission (BSEC) fined Libra's directors Tk 120 million in total for non-compliance in 2017.
This time, the regulator is yet to punish the company or its directors for the delay in publishing financial statements.
Libra Infusions, a manufacturer of intravenous fluids, widely known as IV Solution, started business in 1985.
babulfexpress@gmail.com